Prof Tripathy speaks at a SABCS 2017 press session about data from the MONALEESA-7 phase III clinical trial.
Adding the CDK4/6 inhibitor ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor–positive (HR-positive), HER2-negative breast cancer.
Read the news story for more.